Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells
are destroyed, resulting in poor blood sugar control. The purpose of this study is to assess
the safety and efficacy of deoxyspergualin (DSG), an immunosuppressant drug, on
post-transplant islet function in people with type 1 diabetes who have not responded to
intensive insulin therapy.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)